EGFR and non-small cell lung carcinoma: While the status of EGFR and KRAS appears to have no effect on the time from primary diagnosis to the development of BM, other gene mutations in NSCLC have been associated with significantly shorter time to development of BM, including those activating PI3K signaling.25